

CITATION REPORT

List of articles citing

Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis

DOI: 10.1080/1744666x.2020.1858803

Expert Review of Clinical Immunology, 2021, 17, 85-99.

Source: <https://exaly.com/paper-pdf/77975468/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
14	Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review. <i>Patient Preference and Adherence</i> , 2021 , 15, 811-834	2.4	6
13	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021 , 20, 102849	13.6	3
12	Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom. <i>Applied Health Economics and Health Policy</i> , 2021 , 19, 735-745	3.4	1
11	Subcutaneous Infliximab, CT-P13 [®] SC: A Profile of Its Use in the EU. <i>Clinical Drug Investigation</i> , 2021 , 41, 1099-1107	3.2	0
10	MiR-144-3p induced by SP1 promotes IL-1 β -induced pyroptosis in chondrocytes via PTEN/PINK1/Parkin axis. <i>Autoimmunity</i> , 2021 , 1-11	3	1
9	Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?. <i>Journal of Pharmaceutical Sciences</i> , 2021 ,	3.9	3
8	CT-P13 SC for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2021 ,	5.1	
7	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.. <i>Advances in Therapy</i> , 2022 , 1	4.1	1
6	Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?. <i>Pharmaceuticals</i> , 2022 , 15, 616	5.2	1
5	Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence. <i>Journal of Inflammation Research</i> , Volume 15, 3259-3267	4.8	
4	Increased susceptibility to pneumonia due to tumour necrosis factor inhibition and prospective immune system rescue via immunotherapy. 12,		0
3	Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics. 2022 , 11, 6173		1
2	Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort. 2022 , 58, 1851		0
1	Biomineralized Nanoscavenger Abrogates Proinflammatory Macrophage Polarization and Induces Neutrophil Clearance through Reverse Migration during Gouty Arthritis.		0